Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference

Rhea-AI Summary

Opthea Limited (NASDAQ:OPT; ASX:OPT), a biopharmaceutical company focused on innovative therapies for retinal diseases, announced that CEO Dr. Megan Baldwin will engage in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference on March 13, 2023, at 2:40 pm ET. This event can be accessed live through registration. Opthea’s lead candidate, OPT-302, is currently undergoing pivotal Phase 3 trials aimed at treating conditions like wet AMD and diabetic macular edema. The company emphasizes the risks associated with biotechnology investments, urging potential investors to seek professional advice.

MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33^rd Annual Healthcare Conference being held virtually on March 13-15, 2023.

Dr. Baldwin’s conversation with Hartaj Singh, Managing Director and Senior Analyst, Biotech Equity Research at Oppenheimer, will take place on Monday, March 13^th at 2:40 pm ET (6:40 am March 14^th AEDT), and can be accessed live by registering at https://wsw.com/webcast/oppenheimer27/opt/2585247. An archive of the presentation will be available for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (Nasdaq:OPT; ASX:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:
U.S.A. & International:		Australia:
Timothy E. Morris, CFO		Rudi Michelson
Opthea Limited		Monsoon Communications
Tel: +1 650-400-6874		Tel: +61 (0) 3 9620 3333
Media:
Hershel Berry
Blueprint Life Science Group
Tel: +1 415-505-3749
hberry@bplifescience.com

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399	Email: info@opthea.com	Web: www.opthea.com

FAQ

When is Dr. Megan Baldwin's fireside chat at Oppenheimer's Conference?

Dr. Megan Baldwin's fireside chat will take place on March 13, 2023, at 2:40 pm ET.

How can I access the live stream of the Oppenheimer Conference where Opthea will present?

You can access the live stream by registering through the provided link in the press release.

What is the status of OPT-302 in the clinical trials?

OPT-302 is currently in pivotal Phase 3 clinical trials for treating retinal diseases.

What diseases is Opthea developing treatments for?

Opthea is developing treatments for wet AMD and diabetic macular edema.

What risks are associated with investing in Opthea Limited?

Investing in Opthea involves risks such as lengthy clinical trials, patent protection uncertainty, and dependency on research success.